Clinical Trial Update: Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients [Phase 2]

View source ↗

Summary

A Phase 1b/2 study of PF-04136309 in combination with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer was terminated, with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Gemzar (gemcitabine)
• PF-04136309 (PF-04136309)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2019-02-04